NEWS
2025年09月22日
iCONM in collaboration with BioLabsでは、10月9日（木）7:00 pmより、ネットワーキングイベント「Support for an Early Biotech ~初期創薬スタートアップへの支援~」を開催します。
今年はBioJapan2025会場近く、Tech Hub Yokohamaでの開催です。最先端の創薬スタートアップや研究者、支援者が集まり、情報交換やネットワーキングを行う絶好の機会となります。
当日は軽食や飲み物もご用意しておりますので、お仕事帰りやBioJapan2025イベント終了イベント終了後にお気軽に立ち寄っていただき、カジュアルに交流をお楽しみいただけます。リラックスした雰囲気の中で、新しい出会いや繋がりを広げる場としてご活用ください。
是非皆さまお誘い合わせの上、ご参加ください！
Support for an Early Biotech
Starting a drug discovery startup? In the early stages, knowledge, facilities, funding, and networks matter more than ever. This event is all about discovering what kind of support is out there for early-stage startups—who provides it and how to access it. It’s a great opportunity for founders, mid-stage teams, VCs, university-industry partners, and other startup supporters to connect and learn!
When
Thursday 7:00-9:00pm, October 9th, 2025
Where
Tech Hub Yokohama
【Address】
2-2-1, Minato Mirai, Nishi-ku, Yokohama City, Yokohama (Yokohama Landmark Tower Site TECH HUB YOKOHAMA)
Program
7:00- Greeting
7:10- Introduction
7:25- Panel Discussion
8:00- Q&A
8:20- Networking
Language
English
Fee
Free
Panelist
Shu Konakahara, AbbVie Ventures
Shu Konakahara, Ph.D. is Managerof JAPAC Strategic Planning &Evaluation at AbbVie GK andScientist in Residence at AbbVieVentures. He has 15+ years ofexperience in academia, biotech,and pharma, specializing inantibody discovery, early clinicaldevelopment in Asia, and precisionmedicine. He is skilled in jointresearch negotiation, businessdevelopment due diligence,leadership, and stakeholdercommunication. He quickly adaptsto new areas, makes timelydecisions, and is passionate aboutadvancing innovative science andbridging pharma with the biotechcommunity.
Hikaru Saito, Saisei Ventures
The career started with a Ph.D. on multidrug resistance under Prof. Ishikawa, followed by compound screening with Prof. Nureki and Nihon Chemiphar, leading to a granted patent. At Astellas, worked as a scientist in formulation, process development, and GMP manufacturing, then on recombinant fibrinogen from transgenic silkworms, which informed later work in cell and gene therapy. After 6 years as a scientist, transitioned into business development at Astellas Innovation Management and later Astellas Venture Management in Silicon Valley. Led global deal processes in RNA, cell and gene therapy, due diligence, financings, fund investments, and partnerships with US/EU VCs. Motivated by curiosity in emerging science and building innovative companies to transform healthcare.
Ariane Doischer, BioM
Ariane Doischer is International Relations Manager at BioM Biotech Cluster Development GmbH, leading international project management and business development to strengthen the biotech ecosystem in Bavaria and beyond. She previously held roles at Sana Kliniken in international marketing and business development, and at Arthrex in corporate sustainability. Earlier, she gained experience in international trade and development at NürnbergMesse, trAIDe GmbH, GIZ, and the German-Costa Rican Chamber of Commerce. She is IPMA Level D certified in project management, skilled in biotechnology, drug development, and clinical studies, and fluent in English, Spanish, and Italian.
Kyoko Mashio, Institute of Science Tokyo
Kyoko Mashio, Professor (Special Appointment) and Deputy Director of the Innovation Design Organization at the Institute of Science Tokyo, where she oversees initiatives within the Greater Tokyo Innovation Ecosystem (GTIE).
She began her professional career at a leading domestic megabank, and subsequently held positions at both domestic and international investment banks, specializing in financial market research and analysis. Her experience at a government-affiliated institution—where she was involved in investments in university-launched startups—served as a turning point, deepening her commitment to supporting entrepreneurial ventures and contributing to the development of innovation ecosystems.
In 2022, she joined the Institute of Science Tokyo to further pursue this mission. Currently, she is actively engaged in advancing the startup ecosystem through the GAP Fund Program, which provides strategic support to academic researchers seeking to commercialize their research through university-based startups. Her work focuses on bridging academia and entrepreneurship to foster innovation-driven enterprises.
Moderator
Susan Chase, BioLabs
Susan Chase is Senior Vice President of Business Development at Bio Innovation Labs (“Biolabs”), the leading global co-working lab platform for early-stage biotech startups. She drives partnerships with pharma, investors, academia, and municipalities to create innovation spaces worldwide. Previously, she directed collaborative programs at The Boston Consortium and MASCO and built expertise in operations and strategy through earlier roles in real estate and risk management. She is recognized for strengths in strategic partnerships, program management, and fostering innovation across stakeholders.
iCONM in collaboration with BioLabsについて
iCONM in collaboration with BioLabsは、羽田空港の対岸に位置する川崎市殿町キングスカイフロントにある「ナノ医療イノベーションセンター（iCONM）」内にある、ライフサイエンス分野のスタートアップを支援するインキュベーション施設です。日本の高い研究技術力に 対して、iCONMの研究支援環境と米国ボストンにあるバイオ領域のグローバルインキュベーター BioLabsの社会実装支援経験の強みをかけ合わせ、スタートアップを支援します。iCONM in collaboration with BioLabsでは、 370種類を超える、微細加工・化学合成・バイオ・動物実験系の共用機器を備えています。【入居者募集中・詳細はこちら】